New hormone therapy for advanced breast cancer after prior treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be ER-positive and HER2-negative, confirmed by a recent biopsy or stored tissue sample.
- Your cancer must have come back while you were on or within 12 months of finishing hormone therapy after your initial treatment.
- You must not have received any cancer treatment (like chemo, immunotherapy, or targeted therapy) for advanced or metastatic disease yet.
- You need to have measurable disease (like tumors that can be seen on scans) or non-measurable disease (like bone-only spread).
- You must be able to perform daily activities without much help (ECOG score 0 or 1).
- If you are premenopausal or a man, you must be willing to take a medication to suppress ovarian function during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This study tests giredestrant, a new hormone-blocking medication, in postmenopausal women with early-stage ER+ breast cancer who have experienced intolerable side effects from their current aromatase inhibitor therapy. The trial will measure how well you tolerate this new drug and how it affects your quality of life.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a combination of two oral medications (abemaciclib and giredestrant) given before surgery to women with a common type of early breast cancer (hormone receptor-positive, HER2-negative). The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests a combination of two drugs (fulvestrant and ribociclib) against other standard treatments for people whose hormone-receptor-positive, HER2-negative breast cancer has returned at least one year after finishing a prior CDK4/6 inhibitor (like abemaciclib or ribociclib). It aims to find a better option for those with advanced disease that can't be cured.
Hear when a new Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.